The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S.

President Donald Trump has won back the White House, and with his win, many health plans are seeing their stocks rise. | ...

Health insurance companies are counting on specialty pharmacy to invigorate their finances as other business lines face headwinds.

UnitedHealth Group Inc. shares rose as much as 9.3% before U.S. markets opened, while shares of Humana Inc. gained as much as ...

Three independent pharmacies have filed separate lawsuits accusing GoodRx, which markets a prescription drug discount card, of conspiring with several pharmacy benefit managers to fix ...

Also, she still views pharmacy benefit management transparency as a key concern for both major political parties, but we ...

The Cigna Group posted strong Q3 2024 results, yet CI stock is down nearly 20% from its 52-week high. See why this may ...

Cigna continues to sidestep significant pressures that have slammed its health insurance peers this year. The majority of the Connecticut-based payer’s business is with employer clients, which ...

Non-commissionable plans: Zeroing out commissions is a way for insurers to stop selling unprofitable products without ...

Baxter covers the Healthcare sector, focusing on stocks such as Humana, CVS Health, and Centene. Cigna has an analyst consensus of Strong Buy, with a price target consensus of $400.11. CI market cap ...

The Rio-based network of independent pharmacies blames drug industry intermediaries known as pharmacy benefit managers.

Specifically, the rumor is The Cigna Group CI is interested in acquiring Humana Inc. HUM. The conjecture caused both stocks to react, as Cigna stock fell 10% as the rumored surfaced on Oct. 18 ...